Funding will accelerate the company’s expansion as the core data infrastructure for enabling accurate, auditable AI workflows across financial services

NEW YORK, May 28, 2026 — Daloopa, the essential data infrastructure for AI and agentic workflows in finance, today announced it has raised $47 million in Series C funding led by Brighton Park Capital, with participation from Squarepoint Capital, Touring Capital, and Nexus Venture Partners. This funding will accelerate Daloopa’s platform growth as investment firms increasingly move AI systems from experimentation into production workflows, where accuracy and reliability are non-negotiable — and expand the company’s team across engineering, product, and go-to-market.

As AI agents power financial workflows, the limiting factor is whether the systems are grounded in reliable data. In high-stakes use cases like valuation, earnings analysis, and portfolio modeling, even small inconsistencies such as misaligned fiscal calendars or inconsistent metric definitions can significantly impact outcomes.

Before structured data infrastructure, analysts were forced to spend hours manually collecting and entering data from company filings, and validating whether each datapoint was correct. AI tools also face a data accuracy problem as most rely on web-sourced inputs that are not standardized or source-linked, inheriting those inconsistencies and producing outputs that are often unreliable.

Daloopa addresses this by providing structured, source-linked financial data that investors can reliably use. The platform now covers over 5,500 public companies globally, delivers up to 10 times more data points per company than other providers, and each datapoint is linked to its original source for auditability. Investment firms trust Daloopa to power workflows ranging from quarterly analysis and scenario modeling to AI-assisted research and reporting.

“We’re seeing firms move from early experimentation toward deploying AI in real investment workflows, and that changes the requirements entirely,” said Thomas Li, CEO of Daloopa. “It’s no longer enough for models to simply generate answers; they must be accurate and fully traceable. Our focus is on building the data infrastructure that makes that possible, so firms can trust what AI is producing.”

The funding follows a series of recent product and partnership milestones that position Daloopa at the center of the emerging AI investment research stack. The company recently:

• Expanded access to its data through MCP connectors with OpenAI’s ChatGPT, Anthropic’s Claude, Perplexity, and Rogo – bringing structured financial data directly into the tools analysts already use
• Published a benchmark study showing AI agent accuracy improved up to 71 percentage points, when grounded in structured, auditable financial data versus web-based retrieval
• Added new platform capabilities, including programmatic access via API, as well as cloud-native delivery via Snowflake, Databricks, and AWS S3.

Daloopa is also introducing a Partner API, unlocking third party product use cases. The new offering enables select partners and startup developers to leverage best-in-class financial data to build AI workflows and to reference within their product suite.

Together, these developments underscore a broader shift in the market: the bottleneck in AI-driven finance is not model intelligence, but data infrastructure.

“Daloopa is solving one of the most consequential data challenges in financial services,” said Tim Drager, Partner at Brighton Park Capital. “As AI becomes embedded in financial decision-making and core investment workflows, the firms that succeed will be those with the strongest data foundations. Daloopa has built exactly that and is already trusted by over 160 financial institutions, which speaks to both the quality of the platform and the urgency of this problem. We are thrilled to partner with Thomas and the team as they continue to define this category.”

Brighton Park Capital was supported by Special Advisor, Phil Hadley, former CEO and Chairman of Factset in their evaluation of Daloopa.  

That momentum is also reflected in how investment firms are engaging with Daloopa. A growing number of customers are already using the platform to operationalize AI in production workflows, and in some cases, firsthand experience with the technology has also led to investment conviction.

The company has also continued to scale rapidly, doubling revenue over the past year while expanding coverage and deepening integrations across the AI ecosystem. As firms push toward greater automation, Daloopa is becoming a core part of the infrastructure that enables AI and agentic workflows in financial services.

About Daloopa
Daloopa is the financial data layer powering the finance ecosystem with the most accurate and comprehensive data. Its proprietary platform sources, structures, and distributes this historical financial dataset covering 5,500+ public companies globally. Analysts at the world’s top investment firms trust Daloopa’s workflow solutions to save valuable time and accelerate their decision making. Daloopa also provides the critical AI data infrastructure that underpins the best financial agents and is trusted by the world’s most preeminent AI companies.

For more information or to request a demo, visit daloopa.com.

About Brighton Park Capital
Brighton Park Capital is a New York-based investment firm focused on entrepreneur-led, growth-stage software, healthcare and tech-enabled services companies. The firm invests in companies that provide highly innovative solutions in partnership with great management teams. Brighton Park brings purpose-built, value-add capabilities that match the unique requirements of each of its companies. For more information about Brighton Park Capital, please visit www.bpc.com.

Media Contact
Christina Scott
Vice President of Marketing
[email protected]

SOURCE Daloopa

The round was co-led by Heavybit and Seligman Ventures, and will support the launch of Rote, a local execution layer that makes agent workflows dependable in production.

SAN FRANCISCO, May 28, 2026 — Modiqo, an AI infrastructure company, today announced $3 million in pre-seed funding to help companies turn AI experiments into systems they can actually depend on. The round was co-led by Heavybit and Seligman Ventures, with participation from Irregular Expressions and angel investors.

Most companies have discovered that getting an AI agent to work once is easy. Getting it to work reliably — every day, across changing models and volatile APIs — is where the trouble starts. Teams spend more time rebuilding workflows that quietly broke overnight than getting new value from AI.

“AI workflows today are like sandcastles. They look impressive when you build them, then wash away the moment anything changes,” said Chetan Conikee, Founder and CEO of Modiqo. “Companies are paying their best people to rebuild the same things again and again. Rote captures what worked the first time and locks it in, so teams can move forward instead of starting over.”

With this funding, Modiqo launched Rote, a tool that watches what an AI agent does when it succeeds, then turns that success into a reliable, repeatable process the company owns. Rote helps teams:

• Make AI work the same way every time — no more surprises when a model, APIs or system updates
• Plug into the tools you already use — without expensive engineering work
• Cut AI costs significantly — by reusing proven workflows instead of paying for the AI to figure them out from scratch each time
• See exactly what’s happening — what ran, when, and what it cost

“The industry is quickly realizing that building capable AI agents is only part of the challenge, operating them reliably at scale is the harder problem,” said Umesh Padval, Managing Partner, Seligman Ventures. “Modiqo is building a critical foundational AI infrastructure layer that enables teams to deploy AI workflows reliably at a fraction of the token cost. I am excited to partner with Chetan again to build a successful company.”

“Today’s AI agents are impressive in the demo and unreliable in production,” said Joseph Ruscio, General Partner at Heavybit. “The deeper problem isn’t agent capability — it’s that every agent run is effectively a one-off chat log rather than an artifact that can be proven and iterated on. Teams pay the same rediscovery tax over and over, and the abstractions emerging around them weren’t built to survive change. Modiqo’s Rote captures what worked the first time and turns it into deterministic code — cutting token usage, reserving inference for the parts that genuinely need it, and reining in the context bloat plaguing today’s agent stacks. Chetan and his team are building the execution layer agents need to graduate from experiment to production infrastructure, and Heavybit is proud to back them from Day 0.”

“Every serious team running agents is hitting the same wall: reliability, cost, and reproducibility,” said Jean Sini, founding partner at Irregular Expressions. “Modiqo is the first team I’ve seen attack all three at the execution layer rather than the prompt layer.”

To learn more and request a demo, please visit: https://www.modiqo.ai/

About Modiqo

Modiqo is building the infrastructure layer for reliable AI agent workflows. Its platform, Rote, enables teams to move beyond one-off success by turning working executions into reusable, repeatable processes. Designed for organizations deploying AI across real-world operations, Modiqo helps teams reduce manual rework, improve consistency, and scale workflows with confidence.

SOURCE Modiqo

Silicon Road Ventures leads latest investment round as Rep AI expands its unified AI platform designed to improve conversion, customer experience, and operational efficiency

NEW YORK and TEL AVIV, Israel, May 28, 2026 — Rep AI, an AI platform purpose-built for ecommerce brands and online retailers, today announced it has raised $6.2 million in strategic follow-on funding. The round was led by Silicon Road Ventures, with participation from Osage Venture Partners, Flashpoint Venture Capital, and strategic investor Zendesk.

This latest raise marks the second tranche of Rep AI’s funding in approximately 20 months, building on the company’s initial $8.2 million Series A round announced in August 2024. The new capital will accelerate product innovation, expand market reach, and support enterprise growth as Rep AI strengthens its position in the evolving ecommerce AI sector.

Rep AI’s platform helps brands unify customer engagement across the full shopping journey – from identifying shopper intent before purchase to improving conversion and streamlining post-purchase support. By consolidating fragmented AI and customer experience tools into a single platform, Rep AI addresses growing demand for more efficient, revenue-focused ecommerce operations.

“ecommerce brands are increasingly overwhelmed by disconnected technology stacks that create operational silos and missed revenue opportunities,” said Yoav Oz, co-founder and CEO, Rep AI. “This funding further validates our vision of building a unified AI operating system for ecommerce – one that helps brands better understand shopper behavior, improve conversion, and deliver stronger customer experiences from first interaction through long-term loyalty.”

“The industry is moving beyond isolated AI tools toward integrated systems that can influence the entire customer journey across ecommerce,” said Shauli Mizrahi, co-founder and Chief Technology Officer, Rep AI. “Our focus has always been on building an infrastructure that drives measurable business outcomes while simplifying how brands deploy and scale AI.”

As enterprise AI adoption accelerates, investors are backing platforms that can move beyond fragmented experimentation and deliver scalable business value. According to McKinsey’s 2025 State of AI report, 78% of organizations now use AI in at least one business function, reflecting a significant shift from experimentation to operational deployment. However, many organizations continue to face challenges tied to siloed AI systems and fragmented implementations – creating demand for more unified, enterprise-grade platforms.

“Brands are seeking scalable, revenue-driving agentic AI infrastructure rather than isolated point solutions,” said Sid Mookerji, Managing Partner at lead investor, Silicon Road Ventures. “Rep AI is emerging as a leader in ecommerce’s fastest-growing technology categories by replacing fragmented systems with a more cohesive, intelligent platform.”

Zendesk’s strategic investment represents more than just capital – it signals validation from one of customer experience technology’s most influential companies and reinforces the growing convergence of customer service, sales, and revenue generation.

“A great retail experience feels like a knowledgeable sales concierge, one that asks the right questions to understand your needs, knows the products inside and out, and can help with everything from discovery to returns. True AI integration in retail requires more than a chatbot; it requires a deep understanding of shopper behavior and product data. Rep AI’s platform demonstrates how behavioral AI can bridge the gap between site visits and completed purchases, offering a personalized concierge at scale. We’re pleased to support the team as they continue to refine the intersection of CX and commerce,” said Adrian McDermott, CTO, Zendesk.

About Rep AI

Rep AI is the AI operating system for ecommerce — a single agentic platform that works across the full customer journey, from behavioral intent detection on arrival through personalized sales guidance, conversion optimization, and post-purchase support. Built on proprietary behavioral AI and large language models, Rep AI proactively engages shoppers at the moment of highest intent, ingests each brand’s voice and product knowledge, and delivers shared shopper intelligence across marketing, CX, and sales teams simultaneously. Customers including Proof Wallets, VIBAe, K2, Unclaimed Bagage, Satya Jewelry, HigherDOSE, OLLY, Cloth & Paper, Bikes Online, and NutraBio use Rep AI to drive compounding revenue growth. Rep AI is backed by Silicon Road Ventures, Osage Venture Partners, Flashpoint Venture Capital, and Zendesk.

For more information, visit hellorep.ai.

Media Contact:
Erin Farrell Talbot
917-232-9309
[email protected]

SOURCE Rep AI

Garner partners with almost 800 leading companies, who see an average 12 percent reduction in annual healthcare spend

NEW YORK, May 28, 2026 — Garner Health, a leading digital platform that helps patients find the best healthcare providers using better data and smarter financial incentives, has closed a $100 million Series E round, led by Index Ventures with participation from existing investors including Kleiner Perkins, Redpoint, Thrive, Sequoia, Founders Fund, and Kaiser Permanente Ventures. The round brings Garner’s valuation to $2.74 billion.

The round reflects growing demand from employers, health plans, and health systems alike for better ways to help Americans find high-quality doctors while reducing healthcare costs. Garner partners with almost 800 customers, including USA Today, Paylocity, and the University of Oklahoma.

Garner’s gross annual recurring revenue is approximately $200M, and has more than doubled for five years in a row.

Alongside the financing, the company recently conducted a second tender offer for employees. 

“Healthcare doesn’t change through incremental tweaks—it changes when consumers finally have the information and incentives they need to make better decisions about their care,” said Nick Reber, Garner Health CEO. “Our mission at Garner is to fundamentally realign the system around quality by empowering people to choose the doctors who deliver the best outcomes. When you give consumers the right data and align incentives around better care, the entire healthcare system will change for the better.”

“The American healthcare system pays doctors to do things to you, not for you. Garner is quietly fixing that,” said Jahanvi Sardana, Partner at Index Ventures. “By using AI to make physician quality measurable for the first time, they’ve built the market mechanism healthcare always needed – one where employers, hospitals, and patients can finally see who delivers better outcomes, and the system rewards them for it. It’s one of the most important applications of AI in healthcare today.”

Better healthcare at lower prices is a universal need from every American

The single most important decision in healthcare is which doctor patients see. But historically, people rarely have reliable information about which providers consistently deliver the best outcomes.

Garner is changing that.

Garner’s platform analyzes billions of healthcare data points to identify the providers who deliver the best results and then aligns incentives so employees and their families can access those doctors more easily.

When members choose high-performing providers through Garner, employers cover most or all of their out-of-pocket costs—leading to better care and lower costs for employees. Importantly, the result is also lower overall healthcare spending, as these top-performing doctors are more likely to follow the latest medical guidelines, avoid unnecessary procedures, and help patients get healthy faster.

Archer-Daniels-Midland, a leading global agriculture company with over 44,000 employees, has partnered with Garner to transform their benefits program. “At ADM, we’re committed to creating a culture of care where our employees feel supported in every aspect of their wellbeing,” said Molly Strader Fruit, ADM’s VP of Total Rewards. “Navigating healthcare shouldn’t add stress to already busy lives, and Garner has been an important partner in helping us remove that friction, connecting our people to high-quality, eligible providers and making care more accessible. Together, we’re helping ensure our employees can focus on what matters most.”

Garner is leveraging AI to help more than 2.5 million people get better care

Garner’s AI strategy operates on two powerful fronts: scaling the measurement of clinical quality and transforming the member experience.

Behind the scenes, the newly developed Garner Research Agent represents a massive step forward in the ability to quickly and accurately measure and understand clinical performance at scale. This advanced AI is built to automatically review the latest medical literature and translate it into sophisticated algorithms that parse the quality and efficiency of every doctor in the country. By continuously integrating cutting-edge medical research and Garner’s longitudinal patient data, the Research Agent ensures Garner’s clinical metrics remain the most rigorous and up-to-date in the industry.

On the member-facing side, the recently launched Garner Assistant provides a new way for users to effortlessly navigate their care. Serving as a one-stop shop, the Assistant helps members handle many of the most common (and laborious) healthcare tasks, including:

• Finding high-quality doctors
• Viewing appointment availability and booking visits
• Understanding health plan and benefit details
• Checking claims, payments, and reimbursement status
• Getting guidance on how to make the most of their healthcare coverage

As new AI tools flood the market, employers and employees alike need to know that not all technologies are created equal. Both the Research Agent and the Garner Assistant are powered by Garner’s industry-leading claims database—covering over 60 billion medical records from 320 million patients—alongside over 550 proprietary clinical metrics. This infrastructure allows Garner to identify the best providers in the nation with unparalleled precision, while the company’s novel approach to incentives drives more than 46% of eligible members to use the platform.

Together, these AI innovations streamline and enhance the member experience while remaining rooted in the evidence-based infrastructure that drives meaningful outcomes for Garner’s customers and their employees.

What’s Next

Demand for Garner continues to grow as employers search for real solutions to rising healthcare costs. At the same time, the company has inked partnerships with leading healthcare providers including Mercy, Atlantic Health, Teladoc, and Marathon Health. These providers use Garner’s data-driven tools to drive improved performance, for example improving quality in their practice and identifying the highest-performing specialists for referrals.

The new infusion of capital will allow Garner to continue to expand its provider quality platform, scale AI-powered product innovation, and bring Garner to millions more members.

About Garner Health Garner Health is a technology company on a mission to transform the healthcare economy and deliver high-quality and affordable care for all. Garner uses one of the nation’s most robust medical datasets – covering over 60 billion medical records – to identify the best doctors in the nation. Garner then creates meaningful financial incentives for patients to see these providers. The result: employees pay on average 80% less out-of-pocket to see the best doctors, while employers see an average 12% reduction in total healthcare spend in the first year alone. Garner has almost 800 clients and partners with some of the largest employers, health plans and providers in the country. For more information, visit www.garnerhealth.com.

Media Contact: [email protected]

SOURCE Garner Health Technology

$1.3 billion Senior Secured Notes offering marks the first bond offering of its kind in the data center sector to support the simultaneous development of multiple sites serving different customers

NEW YORK, May 28, 2026 — Edged US today announced it has secured nearly $2 billion in cumulative financing year-to-date, accelerating the company’s expansion of sustainable, AI-ready digital infrastructure across key U.S. markets in Atlanta, Chicago and Council Bluffs.

Central to this milestone is the successful pricing of a $1.3 billion Senior Secured Notes offering in April 2026 – the first bond offering of its kind to support the simultaneous development of multiple sites serving different customers. The offering supports the development of two large-scale build-to-suit data centers at the Edged campuses in Atlanta and Chicago under long-term leases. Morgan Stanley served as Lead Left Bookrunner.

The year-to-date financing execution also includes a construction loan supporting the continued development of Edged US’ 200 MW campus in Council Bluffs, Iowa, with TD Securities and Crédit Agricole CIB serving as Coordinating Lead Arrangers.

“Demand for high-performance digital infrastructure continues to accelerate at an unprecedented pace, and this financing momentum positions us to move quickly and strategically alongside our customers,” said Bryant Farland, Chief Executive Officer of Edged US. “We are proud to continue expanding our platform with infrastructure designed to support the next generation of AI and cloud growth while remaining deeply committed to efficiency, sustainability, and responsible long-term development.”

The milestone reflects strong market confidence in Edged US’ differentiated approach to digital infrastructure, which combines ultra-efficient design, waterless cooling technology, and scalable deployment capabilities purpose-built for AI training and inference workloads. The company’s ThermalWorks cooling technology consumes zero water in daily operations, and its data centers deliver a targeted design PUE of 1.15 portfolio-wide with liquid-to-chip cooling capabilities for next-generation compute environments.

Edged US continues to expand its footprint in strategic metro markets across North America, with operational and in-development campuses spanning Atlanta, Chicago, Columbus, Council Bluffs, Dallas, Des Moines, Kansas City, and Phoenix.

“As the market continues evolving, customers increasingly need partners that can deliver capacity quickly, efficiently, and responsibly,” added Farland. “This financing milestone underscores confidence in our ability to execute and continue building the infrastructure that powers the future of the digital economy.”

About Edged US

Edged US develops and operates ultra-efficient, AI-ready data centers for hyperscalers, technology providers, and large enterprises across major U.S. markets. With a gigawatt-scale platform expanding across North America, Edged US provides scalable, sustainable infrastructure that meets today’s AI demand and tomorrow’s growth. For more information, visit www.edged.us.

SOURCE Edged

Led by Battery Ventures, the round will scale Triomics’ AI platform across cancer centers nationwide and deepen life-sciences partnerships

NEW YORK, May 28, 2026 — Triomics, an oncology AI company helping cancer centers operationalize complex clinical information, today announced it has raised $22 million in Series B financing led by Battery Ventures, with participation from existing investors Nexus Venture Partners, Lightspeed and Y Combinator, alongside strategic backers Oncology Ventures and Precision Health Informatics, a wholly-owned subsidiary of Texas Oncology. This round brings Triomics’ total funding raised to date to more than $36 million.

The new capital will be used to accelerate adoption across health systems, oncology networks and life sciences organizations; grow Triomics’ AI/engineering and forward-deployed teams; and advance the company’s AI agents for clinical care and research. Triomics is already working with leading cancer centers like Memorial Sloan Kettering Cancer Center (MSK), MD Anderson, Yale Cancer Center and its partner Smilow Cancer Hospital, and Mount Sinai Tisch Cancer Center, as well as some of the nation’s largest community oncology practices, such as Texas Oncology.

“Oncology faces an information burden at a scale legacy systems were never designed to handle, and that burden can stand in the way of better outcomes,” said Sarim Khan, co-founder and CEO of Triomics. “Clinicians, research coordinators and medical assistants are working against records that have become too large and too dynamic to process manually. We built Triomics to turn that complexity into usable intelligence inside the workflow, purpose-built for oncology. This financing allows us to bring that infrastructure to many more cancer centers and improve care for cancer patients.”

Beyond provider workflows, Triomics has built a broader oncology network that helps life- sciences organizations with their critical clinical-trial operations. The company believes the combination of deep provider workflow integration across cancer centers, combined with oncology-specific AI infrastructure, creates a durable foundation for the next generation of care and research applications.

Transforming Oncology’s Data Overload into Actionable Intelligence
Cancer care is no longer constrained by a lack of information; it’s limited by the ability to use the data that already exists. A single patient history can span hundreds of narrative-heavy clinic notes, pathology and radiology reports, biomarker results, outside records, prior treatments, and ever-evolving trial criteria and guidelines. Yet the workflows required to make that information usable have remained overwhelmingly manual.

“Oncology is the hardest place to build AI, yet the most important,” said Hrituraj Singh, co-founder and CTO of Triomics. “Getting a model to reason reliably across thousands of pages of notes, pathology, imaging and evolving trial criteria, and show its work, is what separates a demo from software that clinicians actually use. We’ve spent four years building that foundation and this round lets us push even further.”

Founded in 2021 by Khan and Singh, Triomics is building a platform that uses AI agents to read the full longitudinal patient record and converts unstructured information into structured, explainable outputs. Then, it delivers those insights directly into clinical and operational workflows. Unlike lightweight summarization tools, every output is source-backed and verifiable inside the clinician’s workflow. The platform supports proactive clinical trial matching, pre-visit chart review and preparation, and oncology data abstraction for registry, quality improvement and operational use cases.

Cancer centers rely on Triomics to expand trial access, reduce the burden of manual chart review, improve visit preparation and generate higher‑quality structured data for research and operations. Published results show that users of the company’s product have increased trial matches by 40% and trial enrollments by more than 30%, while also reducing chart review times by 67%. The platform has received peer-review validation in Nature Digital Medicine and was presented at ASCO, underscoring growing demand for AI that can operate reliably on the full patient record.

“We are excited to partner with Triomics, our selected solution for oncology clinical trial matching, to extend our collaboration to an AI-enabled method for cancer registry abstraction and reporting. This activity is labor intensive, subjective and challenging to complete in a timely manner. Our goal is to produce autonomous chart abstraction of clinical registry quality that can be rapidly reviewed and finalized for reporting by human registrars to comply with mandatory state, federal and professional society reporting obligations,” said Lee Schwamm, MD, chief digital health officer, Yale New Haven Health System, and associate dean, Digital Strategy & Transformation, Yale School of Medicine.

“Triomics built what oncology has always needed: AI infrastructure that actually works on the full patient record,” said Brandon Gleklen, principal at Battery Ventures, who is joining the Triomics board of directors. “We are live at some of the top cancer centers and demonstrating measurable outcomes—faster enrollment, less manual chart review—and the same underlying AI infrastructure already powers multiple distinct workflows with no redundant integrations. That kind of platform leverage, inside a customer base this strong, is rare at this stage.”

About Triomics
Triomics is an oncology AI company building the infrastructure that turns complex, longitudinal cancer records into structured, explainable intelligence. The company’s platform supports patient trial matching, pre-visit chart prep, and oncology data abstraction, helping care teams, research teams, and health systems act faster on the information already in the chart. Headquartered in New York, Triomics is backed by Battery Ventures, Lightspeed, Nexus Venture Partners, Y Combinator and Oncology Ventures. For more information, visit www.triomics.com.

SOURCE Triomics

Transformation Capital leads $21M investment in Solstice, enabling pharma brands to slash medical, legal, and regulatory marketing review cycles from weeks to less than 48 hours

NEW YORK, May 28, 2026 — Solstice, the AI-native marketing agency accelerating pharma commercialization, today announced it has raised $21 million in Series A funding led by Transformation Capital with participation from Twelve Below, Virtue Ventures and others. The round brings total funding to approximately $25 million. The capital will fuel go-to-market expansion, accelerate product development and enable Solstice to grow its team across product and customer-facing functions. Few business challenges are as high-stakes and time-sensitive as commercializing a new drug or medical product.

Biopharma companies are projected to spend more than $100 billion on commercialization efforts. Yet, the process of transforming clinical evidence into compliant marketing campaigns has barely changed over the past decades. A single marketing asset, even something as routine as an email, often takes three months to move through medical, legal and regulatory (MLR) review. With shrinking patent exclusivity windows, every additional month of delay means fewer patients receiving a therapeutic. 

“We built Solstice to help life sciences teams bring therapeutics to market faster by unifying content creation, medical review and performance insights in a single AI-native system that generates beautiful content, grounds every claim in clinical evidence before MLR review and measures what content will actually move the needle in driving physician and patient action,” said Aris Saxena, co-founder and CEO of Solstice. “Our customers used to run three review cycles per asset; now they run one or two at most, and content that used to take months goes out in 10 days. Most importantly, they create more personalized, higher-performing content that helps them compete in increasingly crowded biopharma markets.”

Solstice pairs AI-native technology with in-house subject-matter experts to replace traditional workflows among marketing agencies, regulatory teams and in-house marketers. The platform ingests a brand’s clinical data, FDA documents and approved literature to build a grounded understanding of the product to quickly generate digital campaigns, programmatic ads and patient and healthcare provider communications. Every asset is created and reviewed using a combination of Solstice’s proprietary pharmaceutical marketing models as well as the company’s in-house experts for both compliance and taste, and is scored on its likelihood of MLR approval for review before it reaches the regulatory team. Solstice then measures content performance to predict the highest-performing assets and produce novel content that drives physician and patient engagement. The result is a faster path to attributable, compliant content without sacrificing the expertise pharma brands require.

“Before Solstice, getting a single marketing asset through MLR could take weeks of back-and-forth that delayed launch and healthcare provider outreach,” said Kristine Saffrin, marketing director, Alexion Pharmaceuticals. “Now we move from draft to approved in days, which means our team can actually deliver on the personalization and pace a modern brand demands.”

Solstice customers launch campaigns 12 times faster than they would via traditional agencies, enabling content to move from concept to MLR submission in under 48 hours and be market-ready in roughly 10 days. As a result, teams are producing nearly three times more high-quality, tasteful and effective content per quarter and reducing the average number of MLR reviews per asset from 3.2 rounds to 1.2 rounds.

“Bringing a new drug to market is one of the most valuable and heavily regulated processes in healthcare, yet the commercialization workflow has barely changed in decades,” said Vinay Shah, Partner and Founding Team Member at Transformation Capital. “Solstice is using AI to fix that — helping pharma brands move faster without compromising compliance. Customers are already seeing real results via faster reviews and meaningful cost savings. We’re thrilled to lead this round and partner with the Solstice team.”

The Series A follows a year of rapid commercial growth for the company, which now serves over a dozen pharmaceutical companies, including several of the top 20 pharmaceutical brands across therapeutic areas, including oncology, immunology and metabolic diseases.

To learn more or request a demo, visit www.solsticehealth.co.

About Solstice:
Solstice is the AI-native marketing agency for pharma brands. The company pairs AI technology with in-house experts to generate, review and activate compliant marketing content at speed, replacing the traditional handoffs between agencies, regulatory teams and in-house marketers. Headquartered in New York, Solstice is backed by leading investors including Transformation Capital, Twelve Below, Virtue Ventures, Ford Street Ventures, Go Global Ventures, Cory Capital and others. For more information, visit https://www.solsticehealth.co/.

Contact: 
BAM by BIG for Solstice
[email protected]

SOURCE Solstice Health

TAMPA, Fla., May 28, 2026 — Psilera Inc. (“Psilera”), a leading biopharmaceutical company pioneering next-generation neuroplastogens and psychedelic therapies, today announced the successful closing of an oversubscribed $8.8 million Series Seed extension funding round led by a syndicate of institutional and strategic investors. 

The company intends to use the funds to advance its lead clinical asset, PSIL-006, towards first-in-human trials in 2027. PSIL-006 is a first-in-class neuroplastogen designed to harness the therapeutic benefits of traditional psychedelic compounds while minimizing hallucinogenic effects and cardiovascular risks.

“This funding marks a pivotal inflection point for Psilera,” said Dr. Chris Witowski, Co-Founder and CEO of Psilera. “With the continued support of our investors, we are now fully resourced to transition from a discovery-stage research company to a clinical-stage organization. Our mission is to provide safe, effective, and accessible treatments for patients suffering from a range of neurological conditions, and this capital ensures we remain on track for our first-in-human trials in 2027.”

Dr. Witowski continued, “We are pleased to see support by the Administration to increase access to psychedelic drugs and expedite the development of innovative treatments with the recently signed U.S. Executive Order, ‘Accelerating Medical Treatments for Serious Mental Illness.’ With the renewed focus from key regulatory agencies, we look forward to working with them to fully develop PSIL-006.”

The infusion of capital follows the achievement of several significant milestones, including:

• The appointment of distinguished neuroscience industry expert Magali Haas, MD/PhD, as Chief Medical Officer;
• Receipt of an NIH funding award of up to $2 million for IND-enabling studies of PSIL-006 in alcohol use disorder (AUD)
• Execution of a strategic licensing agreement with atai Life Sciences (now AtaiBeckley) for its DMT patent portfolio.

About Psilera
Psilera is a leading biopharmaceutical company pioneering next-generation psychedelics and neuroplastogens. Their programs span a wholly owned pipeline of novel therapeutic neuroplastogens, including the lead compound PSIL-006. With a deep commitment to scientific excellence and to improving the patient experience, Psilera pioneers and engineers novel therapies through next-generation precision neuropharmacology. Learn more by visiting www.psilera.com.

Contact Information:
Investors: Monique Kosse, Gilmartin Group
[email protected]

Media: Katie DeMarsh, Director of Marketing
[email protected]

SOURCE Psilera, Inc.

The company is building an AI-native platform that connects every payor-provider contract to the operations that depend on it, from negotiation and modeling to payment and reconciliation.

NEW YORK, May 28, 2026 — Kubera Health today announced it has raised $6.5 million in seed funding led by Upfront Ventures, with participation from Company Ventures, Dria Ventures, and SemperVirens. The company is building the contract-to-payment system of record for American healthcare: the missing infrastructure layer between the agreements that govern payment and the systems that execute them.

The American Medical Association has estimated that one in five commercial claims is processed inaccurately, a rate that has barely moved in over a decade. It contributes to a U.S. healthcare administrative burden that now runs approximately $1 trillion a year, with hospital bad debt up 10% in 2025 alone. The contract and the claim have never actually been connected, and existing tools all work downstream of that disconnection.

Every dollar moving between a payor and a provider is governed by thousands of pages of contracts, amendments, fee schedules, and payor policies, with carveouts, modifiers, and reimbursement rules buried throughout. In nearly every healthcare organization, those documents live in shared drives, disconnected from the claims systems that process payment. Providers lose between 3% and 10% of net revenue annually to inaccurate payments, while payors spend billions adjudicating the resulting disputes. Patients are left paying out-of-pocket with little to no explanation.

For decades, the industry has tried to manage around this disconnection rather than fix it. Healthcare’s response to payment disputes has historically been more staff. Now we’ve added AI: payor models trained to deny and downgrade within seconds, provider models trained to appeal and recode in response. The administrative burden grows with every cycle — what the industry now calls the “Battle of the Bots.” Kubera is building the layer underneath: a preventative and auditing system that brings accountability to payment trends and enforces what every contract actually says.

Kubera turns a customer’s full set of payor-provider agreements into structured rules that run continuously against claims and payment data. Contract Intelligence and the Contract Modeler organize the document portfolio, track deadlines, benchmark rates and terms against the market, and let contracting teams model changes against historical claims before they sign. Payment Auditing and Policy Intelligence apply that logic against actual payments, surface discrepancies with the contract reasoning attached, and bring payor coverage rules into the same system to prevent disputes before they start.

Roja Garimella, MD, founded Kubera Health after concluding from inside Humana and Commonwealth Care Alliance that healthcare’s biggest barriers to better care weren’t clinical, but financial.

“I went into medicine expecting to spend my career on care delivery. The hardest problems I ran into were the ones nobody was supposed to talk about: billion-dollar payment decisions running through spreadsheets, and an industry betting its future on value-based care without the contract and payment infrastructure to support it. That’s what Kubera is building,” said Roja Garimella, founder and CEO at Kubera Health.

Kubera Health partners primarily with mid-to-large health systems with complex managed care operations. Every customer to date has expanded their engagement with Kubera, including Los Angeles-based Hollywood Presbyterian Medical Center.

“Kubera has become an extension of our managed care team,” said Deb DuRoff, FACHE, Vice President of Managed Care at Hollywood Presbyterian Medical Center. “Our contracts and reimbursement methodologies are some of the most complex in healthcare, and we needed a partner sophisticated enough to model them and validate payments against them.”

The thesis behind the round is that fixing this layer is structurally different from improving the workflows on top of it.

“Kubera is rebuilding healthcare’s broken payment foundation, turning contracts into code that runs against claims, so payors and providers finally operate from the same source of truth instead of fighting over the gaps between two different ones,” said Kevin Zhang, General Partner at Upfront Ventures. “Roja, a physician who has lived this problem from the payor, provider, and clinical sides, is exactly the founder to build it.”

The new funding will support continued investment in Kubera’s product, engineering, and go-to-market teams as the company expands its capabilities across value-based care and other novel contract structures, builds out a dedicated payment recovery layer, and grows adoption across health systems, provider organizations, and payor networks.

About Kubera Health

Kubera Health is building the contract-to-payment system of record for American healthcare. The platform translates payor-provider agreements into structured rules and applies them continuously to claims and payment data, giving payors and providers a shared source of truth about what should be paid and what actually was. Learn more at kuberahealth.com.

About Upfront Ventures

Upfront Ventures is proud to be an early investor and long-term partner to tech founders and startups. Founded in 1996 in Los Angeles with investing professionals based in LA and San Francisco, Upfront has backed teams across all technology sectors including hard tech, healthcare, gaming, fintech, SaaS, and developer tools. We invest about half of our capital in the fast-growing Southern California ecosystem, with the balance across the country as well as investments in Europe. Learn what we’re about at upfront.com.

SOURCE Kubera Health